Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Delapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 12/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delapril SCHEMBL6511960 | 1.00 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL20840151 | 1.00 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL3205477 | 1.00 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL9725986 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL9725903 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL10533633 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL120907 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL9725914 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL28170907 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL1133648 | 0.98 | ACE (0.57) | ACEABCB11LMNAPDE3AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14862 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| EP-4611904-A1 | COMPOSITIONS AND METHODS FOR TREATING NF1 AND OTHER CONDITIONS | Liby, Karen (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4525857-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| CN-119325377-A | Method for treating focal segmental glomerulosclerosis with atrasentan | 奇努克治疗公司 | 2025-01-17 | — | — | CN | claimed |
| US-12194032-B2 | Method of treating focal segmental glomerulosclerosis | CHEMOCENTRYX, INC. (US) | 2025-01-14 | — | — | US | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| US-4831184-A | N-substituted-amido-amino acids | RORER PHARMACEUTICAL CORPORATION (US) | 1989-05-16 | — | — | US | claimed |
| WO-1989003691-A1 | POTENTIATION OF ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS | CIBA-GEIGY AG (CH) | 1989-05-05 | — | — | WO | claimed |
| US-4822818-A | ANTIHYPERTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-18 | — | — | US | claimed |
| EP-0281393-A2 | Method for producing indan derivatives | Takeda Chemical Industries, Ltd. (JP) | 1988-09-07 | — | — | EP | claimed |
| EP-0220107-A2 | Use of angiotensin-converting enzyme inhibitors in macular degeneration | MERCK & CO. INC. (US) | 1987-04-29 | — | — | EP | claimed |
| US-4656188-A | Ace inhibitors in macular degeneration | MERCK & CO., INC. (US) | 1987-04-07 | — | — | US | claimed |
| EP-0166257-A2 | Cardiovascular composition | MERCK FROSST CANADA INC. (CA) | 1986-01-02 | — | — | EP | claimed |
| EP-0160307-A2 | Angiotensin converting enzyme inhibitors useful in the treatment of renal diseases | MERCK & CO. INC. (US) | 1985-11-06 | — | — | EP | claimed |
| EP-0051391-B1 | BICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-09-05 | — | — | EP | claimed |
| EP-0051391-A1 | Bicyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-05-12 | — | — | EP | claimed |